收稿日期: 2023-01-29
网络出版日期: 2023-08-31
基金资助
国家自然科学基金(82070227);上海市申康促进市级医院临床技能与临床创新三年行动计划(SHDC2020CR2066B)
Interpretation of Multiple Myeloma Guidelines update (version 2, 2023) of National Comprehensive Cancer Network (NCCN)
Received date: 2023-01-29
Online published: 2023-08-31
多发性骨髓瘤(multiple myeloma, MM)是血液系统第二大恶性肿瘤。随着新药的不断问世,MM患者的生存得到了明显改善,中位生存时间达7~10年,但高危MM患者的生存期仍不足3年,延长高危MM患者生存一直是该领域的研究热点。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)最新发布了2023年第2版《多发性骨髓瘤指南》(以下简称2023.v2版指南)。该指南与2022年第5版比较,在诊断方面的更新主要体现在以表格形式对高危MM作了详细描述,既包括含有1q21获得/扩增的细胞遗传学高危因素,又包括如髓外病变、肾功能衰竭、虚弱等临床高危因素。在治疗方面,2023.v2版指南更新仍强调自体造血干细胞移植在新药时代的重要性,并认为判断患者是否适合移植,需根据初始治疗后患者的情况作动态调整。2023.v2版指南在MM初始诱导治疗中将新一代蛋白酶体抑制剂卡非佐米推荐升级,在维持治疗中将CD38单抗推荐升级;复发后的治疗选择也将这些新药和新一代免疫调节剂泊马度胺的组合列为首选方案。对高危MM的诊断技术和指南更新推荐的新药,目前在我国临床均已有应用,极大提高了临床医师对“临床治愈”MM的信心。全面解读2023.v2版指南更新,有望提升临床医师的诊治水平,进一步改善我国MM患者群体,尤其是高危MM患者的预后。
陶怡, 糜坚青 . 2023年美国国立综合癌症网络(NCCN)《多发性骨髓瘤指南》(第2版)更新解读[J]. 诊断学理论与实践, 2023 , 22(02) : 121 -126 . DOI: 10.16150/j.1671-2870.2023.02.003
Multiple myeloma (MM) is the second most common hematological malignancy. With the continuous advent of new drugs, the survival of MM patients has been significantly improved, with a median survival of 7-10 years. However, the overall survival of high-risk MM patients is still less than 3 years, and extending the survival of high-risk MM has always been a hot topic in this field. The National Comprehensive Cancer Network (NCCN) released the 2nd version of the MM guidelines for 2023 (2023. v2). Compared with the 5th edition of the MM guidelines for 2022, the update of this guideline in diagnosis is mainly reflected in the detailed description of high-risk MM in tabular form, including both cytogenetic high-risk factors containing 1q21 gain/amplification and clinical high-risk factors, such as extramedullary disease, renal failure and weakness. In terms of treatment, the updated guideline still emphasizes the importance of autologous hematopoietic stem cell transplantation in the era of new drugs, and indicates that the judgment of whether patients are suitable for transplantation needs to be dynamically adjusted based on the patients’ condition after initial treatment. 2023. v2 upgrades the recommendation of the new generation proteasome inhibitor carfilzomib in initial induction and CD38 monoclonal antibody in maintenance therapy. The combinations of these new drugs with immunomodulatory drug pomalidomide are also listed as the preferred regimens in relapsed patients. The diagnostic techniques for distinguishing high-risk MM and new drugs recommended in the updated guideline are currently available in China, Which greatly enhanc our confidence in the “clinical cure” of MM. A comprehensive interpretation of the 2023. v2 of the guidelines is expected to improve the diagnostic and therapeutic level of clinicians, and further improve the prognosis of China’s MM patient population, especially high-risk patients.
Key words: Multiple myeloma; Interpretation of guideline; Risk factor
[1] | LIU J, LIU W, MI L, et al. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016[J]. J Hematol Oncol, 2019, 12(1):136. |
[2] | PEMBERTON C J, JOHNSON M L, YANDLE T G, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload[J]. Hypertension, 2000, 36(3):355-359. |
[3] | MERLINI G, LOUSADA I, ANDO Y, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis[J]. Leukemia, 2016, 30(10):1979-1986. |
[4] | D'AGOSTINO M, CAIRNS D A, LAHUERTA J J, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project[J]. J Clin Oncol, 2022, 40(29):3406-3418. |
[5] | WEINHOLD N, SALWENDER H J, CAIRNS D A, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients[J]. Haematologica, 2021, 106(10):2754-2758. |
[6] | ABDALLAH N, BAUGHN L B, RAJKUMAR S V, et al. Implications of MYC rearrangements in newly diagnosed multiple myeloma[J]. Clin Cancer Res, 2020, 26(24):6581-6588. |
[7] | BEKSAC M, SEVAL G C, KANELLIAS N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome[J]. Haematologica, 2020, 105(1):201-208. |
[8] | 陶怡, 金诗炜, 王焰, 等. 髓外病变对初诊多发性骨髓瘤患者预后的影响[J]. 中华血液学杂志, 2023, 44(1): 48-54. |
[8] | TAO Y, JIN S W, WANG Y, et al. Effects of extramedullary disease on patients with newly diagnosed multiple myeloma[J]. Chin J Hematol, 2023, 44(1):48-54. |
[9] | FERNáNDEZ DE LARREA C, KYLE R, ROSI?OL L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage[J]. Blood Cancer J, 2021, 11(12):192. |
[10] | M?LLER M D, GENGENBACH L, GRAZIANI G, et al. Geriatric assessments and frailty scores in multiple mye-loma patients: a needed tool for individualized treatment?[J]. Curr Opin Oncol, 2021, 33(6):648-657. |
[11] | 中国医师协会血液科医师分会,中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5):480-487. |
[11] | Chinese Hematology Association, Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)[J]. Chin J Internal Med, 2022, 61(5):480-487. |
[12] | ROUSSEL M, LAUWERS-CANCES V, WUILLEME S, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results[J]. Blood, 2021, 138(2):113-121. |
[13] | MOREAU P, HULIN C, PERROT A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(10):1378-1390. |
[14] | GAY F, MUSTO P, ROTA-SCALABRINI D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2021, 22(12):1705-1720. |
[15] | SONNEVELD P, ZWEEGMAN S, CAVO M, et al. Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma[J]. Hemasphere, 2022, 6(10):e786. |
[16] | CHARI A, SUVANNASANKHA A, FAY J W, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J]. Blood, 2017, 130(8):974-981. |
[17] | DIMOPOULOS M A, TERPOS E, BOCCADORO M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in pre-viously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(6):801-812. |
[18] | MOREAU P, GARFALL A L, VAN DE DONK NWCJ, et al. Teclistamab in relapsed or refractory multiple mye-loma[J]. N Engl J Med, 2022, 387(6):495-505. |
[19] | MI J Q, ZHAO W, JING H, et al. Phase Ⅱ, Open-label study of ciltacabtagene autoleucel, an anti-b-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed/refractory multiple mye-loma (CARTIFAN-1)[J]. J Clin Oncol, 2023, 41(6):1275-1284. |
[20] | DRAYSON M T, BOWCOCK S, PLANCHE T, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial[J]. Lancet Oncol, 2019, 20(12):1760-1772. |
[21] | TERPOS E, ZAMAGNI E, LENTZSCH S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group[J]. Lancet Oncol. 2021 Mar;22(3):e119-e130. |
[22] | MATEOS M V, DIMOPOULOS M A, CAVO M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 378(6):518-528. |
[23] | FACON T, KUMAR S K, PLESNER T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(11):1582-1596. |
[24] | HUTCHISON C A, BRADWELL A R, COOK M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis[J]. Clin J Am Soc Nephrol, 2009, 4(4):745-754. |
/
〈 |
|
〉 |